Iranian Journal of Pediatrics

Published by: Kowsar

The Efficacy of Cerebrolysin in Improvement of Spasticity in Children with Cerebral Palsy: A Clinical Trial

Mahmoud Reza Ashrafi 1 , 2 , 3 , Amin Shahrokhi 1 , 4 , Ali Reza Tavasoli 1 , 2 , Seyed Ahmad Hosseini 1 , 5 , Morteza Heidari 1 , 2 , Mona Salehi 6 , Elnaz Fattah Dizaji 1 , * and Man Amanat 6 , **
Authors Information
1 Division of Pediatric Neurology, Children’s Medical Center, Pediatrics Center of Excellence, Tehran, IR Iran
2 Department of Pediatrics, Tehran University of Medical Sciences, Tehran, IR Iran
3 Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
4 Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran
5 Department of Pediatrics, Golestan University of Medical Sciences, Golestan, IR Iran
6 Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Iranian Journal of Pediatrics: February 2018, 28 (1); e60840
  • Published Online: February 18, 2018
  • Article Type: Research Article
  • Received: September 5, 2017
  • Revised: December 9, 2017
  • Accepted: January 9, 2018
  • DOI: 10.5812/ijp.60840

To Cite: Ashrafi M R, Shahrokhi A, Tavasoli A R, Hosseini S A, Heidari M, et al. The Efficacy of Cerebrolysin in Improvement of Spasticity in Children with Cerebral Palsy: A Clinical Trial, Iran J Pediatr. 2018 ; 28(1):e60840. doi: 10.5812/ijp.60840.

Copyright © 2018, Iranian Journal of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Sellier E, Platt MJ, Andersen GL, Krageloh-Mann I, De La Cruz J, Cans C, et al. Decreasing prevalence in cerebral palsy: a multi-site European population-based study, 1980 to 2003. Dev Med Child Neurol. 2016;58(1):85-92. doi: 10.1111/dmcn.12865. [PubMed: 26330098].
  • 2. Gulati S, Sondhi V. Cerebral Palsy: An Overview. Indian J Pediatr. 2017. doi: 10.1007/s12098-017-2475-1. [PubMed: 29152685].
  • 3. Oskoui M, Coutinho F, Dykeman J, Jette N, Pringsheim T. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2013;55(6):509-19. doi: 10.1111/dmcn.12080. [PubMed: 23346889].
  • 4. Stavsky M, Mor O, Mastrolia SA, Greenbaum S, Than NG, Erez O. Cerebral Palsy-Trends in Epidemiology and Recent Development in Prenatal Mechanisms of Disease, Treatment, and Prevention. Front Pediatr. 2017;5:21. doi: 10.3389/fped.2017.00021. [PubMed: 28243583].
  • 5. Johnson A. Cerebral palsies: epidemiology and causal pathways. Arch Dis Child. 2000;83(3):279A. [PubMed: 10952658].
  • 6. Hirsh AT, Gallegos JC, Gertz KJ, Engel JM, Jensen MP. Symptom burden in individuals with cerebral palsy. J Rehabil Res Dev. 2010;47(9):863-76. [PubMed: 21174251].
  • 7. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm (Vienna). 2001;108(4):459-73. doi: 10.1007/s007020170067. [PubMed: 11475013].
  • 8. Zhovnir IK, Brozhik NS, Krotiuk LN. [Use of cerebrolysin in patients with cerebral arteriosclerosis]. Vrach Delo. 1973;11:109-11. [PubMed: 4786906].
  • 9. Gershman RN, Vasilenko MA. [Use of cerebrolysin and ATP in treating infantile cerebral paralysis]. Pediatr Akus Ginekol. 1975;(1):22-3. [PubMed: 1228606].
  • 10. Krauss W. [Clinical experience with Cerebrolysin in geriatrics]. Med Welt. 1975;26(42):1937-9. [PubMed: 1186482].
  • 11. Lukhanina EP, Karaban IN, Burenok Iu A, Mel'nik NA, Berezetskaia NM. [Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(7):54-60. [PubMed: 15347036].
  • 12. Noor NA, Mohammed HS, Mourad IM, Khadrawy YA, Aboul Ezz HS. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease. Life Sci. 2016;155:174-9. doi: 10.1016/j.lfs.2016.05.022. [PubMed: 27210889].
  • 13. Cuevas-Olguin R, Roychowdhury S, Banerjee A, Garcia-Oscos F, Esquivel-Rendon E, Bringas ME, et al. Cerebrolysin prevents deficits in social behavior, repetitive conduct, and synaptic inhibition in a rat model of autism. J Neurosci Res. 2017;95(12):2456-68. doi: 10.1002/jnr.24072. [PubMed: 28609577].
  • 14. Sharma HS, Muresanu DF, Sharma A. Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy. Neurodegener Dis Manag. 2016;6(6):453-6. doi: 10.2217/nmt-2016-0037. [PubMed: 27827552].
  • 15. Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Int J Neuropsychopharmacol. 2016. doi: 10.1093/ijnp/pyw024. [PubMed: 27207906].
  • 16. Allegri RF, Guekht A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs Today (Barc). 2012;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721. [PubMed: 22514793].
  • 17. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2013;(1). CD008900. doi: 10.1002/14651858.CD008900.pub2. [PubMed: 23440834].
  • 18. Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. NeuroRehabilitation. 2008;23(3):231-7. [PubMed: 18560139].
  • 19. Morris C, Bartlett D. Gross Motor Function Classification System: impact and utility. Dev Med Child Neurol. 2004;46(1):60-5. [PubMed: 14974650].
  • 20. Nasiri J, Safavifar F. Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial. Acta Neurol Belg. 2017;117(2):501-5. doi: 10.1007/s13760-016-0743-x. [PubMed: 28074392].
  • 21. Liang X. Point injection of cerebrolysin in treatment of child cerebral palsy. Acta Academiae Medicinae Bengbu. 2004;29(4):331-2.
  • 22. Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. doi: 10.3988/jcn.2016.12.1.79. [PubMed: 26365023].
  • 23. Gorbachevskaya N, Bashina V, Gratchev V, Iznak A. Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. Brain Dev. 2001;23 Suppl 1:S90-3. [PubMed: 11738849].
  • 24. Alvarez XA, Sampedro C, Perez P, Laredo M, Couceiro V, Hernandez A, et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003;18(5):271-8. doi: 10.1097/01.yic.0000085765.24936.9a. [PubMed: 12920387].
  • 25. Hartbauer M, Hutter-Paie B, Windisch M. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. J Neural Transm (Vienna). 2001;108(5):581-92. doi: 10.1007/s007020170058. [PubMed: 11459078].
  • 26. Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res. 2002;4(1):59-65. doi: 10.1080/10298420290007637. [PubMed: 12826494].
  • 27. Birch AM, Kelly AM. Chronic intracerebroventricular infusion of nerve growth factor improves recognition memory in the rat. Neuropharmacology. 2013;75:255-61. doi: 10.1016/j.neuropharm.2013.07.023. [PubMed: 23932816].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments